A histopathological comparison of prophylactic effects of Rosmarinic Acid and Oleanolic Acid isolated from Salvia species (sage) in scopolamine induced dementia model
Abstract
Objective: Alzheimer's disease (AD) is the most common form of dementia, can be created in experimental models by using toxins. Possible therapeutic effects of secondary metabolites Rosmarinic (RA) and Oleanolic acids (OA) obtained from Salvia species (sage) were investigated using histopathological and immunohistochemical tecniques in experimental Alzheimer's-like dementia model induced by scopolamine.
Study Design: Male BALB/c mice (n: 48) of 3-4 weeks old, divided into 6 groups; control received only saline(i.p.) for 21 days, scopolamine group received 3 mg/kg of scopolamine (i.p.) between 8-21th days. Scopolamine + RA group received 5 mg/kg RA (i.p.) between days 0 and 21 and 3 mg/kg of scopolamine (i.p.) between 8-21th days. Scopolamine + OA group received 5 mg/kg of OA (i.p.) between days of 0-21 and 3 mg/kg of scopolamine (i.p.) between 8-21th days. RA group received 5 mg/kg RA (i.p.) between 0-21th days. OA group received 5 mg/kg of OA (i.p.) between 0-21th days. Animals were sacrificed under anesthesia, brain tissues were excised and placed in 10% formaldehyde, embedded in paraffin wax. 5 µm sections were cut, stained for histopathological examinations. Immunoreactivity for Beta-amyloid accumulation was observed. ImageJ 153 software was used to analyze IHC figures. Positive signaling for DAB density was calculated, ANOVA test with the post hoc dunnett's or tukey test were applied, p<0.05 was considered statistically significant.
Results: In scopolamine+RA treated group, tissue degeneration was less compared to the scopolamine group. Scopolamine+OA group revealed signs of pyknosis in neurons. The amyloid beta immunoexpression was positive in scopolamine group partially positive in scopolamine+OA group but, negative in RA treated scopolamine group. Intensity of signal in scopolamine group was statistically increased compared to control (p=0.0102). Intensity of signal was reduced in Scopolamine+RA and Scopolamine+OA groups, was statistically significant (p=0.0281 and p=0.0362, respectively).
Conclusion: We suggest that pretreatment of RA and OA decreased beta amyloid formation and ameliorated tissue structure but, further studies with different methods are needed to be commercially available.
Keywords: Scopolamine, dementia, Rosmarinic acid, Oleanolic acid, histopathology, Amyloid beta
Keywords:
Scopolamine, dementia, Rosmarinic acid, Oleanolic acid, histopathology, Amyloid betaDOI
https://doi.org/10.22270/jddt.v11i6-S.5129References
Thomé GR, Oliveira VA, Chitolina Schetinger MR, et al. Selenothymidine protects against biochemical and behavioral alterations induced by ICV-STZ model of dementia in mice. Chem Biol Interact. 2018; 294:135-143. https://doi.org/10.1016/j.cbi.2018.08.004
Maurer K, Volk S, Gerbaldo H. Auguste D and Alzheimer's disease. Lancet. 1997; 349(9064):1546-1549. https://doi.org/10.1016/S0140-6736(96)10203-8
Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, Iadecola C. A beta peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol. 2001; 281(6):H2417-H2424. https://doi.org/10.1152/ajpheart.2001.281.6.H2417
Wang JZ, Liu F. Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol. 2008; 85(2):148-175. https://doi.org/10.1016/j.pneurobio.2008.03.002
Serý O, Povová J, Míšek I, Pešák L, Janout V. Molecular mechanisms of neuropathological changes in Alzheimer's disease: a review. Folia Neuropathol. 2013; 51(1):1-9. https://doi.org/10.5114/fn.2013.34190
Shah D, Blockx I, Guns PJ, et al. Acute modulation of the cholinergic system in the mouse brain detected by pharmacological resting-state functional MRI. Neuroimage. 2015; 109:151-159. https://doi.org/10.1016/j.neuroimage.2015.01.009
Upadhyay P, Sadhu A, Singh PK, et al. Revalidation of the neuroprotective effects of a United States patented polyherbal formulation on scopolamine induced learning and memory impairment in rats. Biomed Pharmacother. 2018; 97:1046-1052. https://doi.org/10.1016/j.biopha.2017.11.008
Klinkenberg I, Blokland A. The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci Biobehav Rev. 2010; 34(8):1307-1350. https://doi.org/10.1016/j.neubiorev.2010.04.001
Portero-Tresserra M, Del Olmo N, Martí-Nicolovius M, Guillazo-Blanch G, Vale-Martínez A. D-cycloserine prevents relational memory deficits and suppression of long-term potentiation induced by scopolamine in the hippocampus. Eur Neuropsychopharmacol. 2014; 24(11):1798-1807. https://doi.org/10.1016/j.euroneuro.2014.10.002
Riedel G, Kang SH, Choi DY, Platt B. Scopolamine-induced deficits in social memory in mice: reversal by donepezil. Behav Brain Res. 2009; 204(1):217-225. https://doi.org/10.1016/j.bbr.2009.06.012
Hatipoglu S.D., N. Zorlu, T. Dirmenci, A.C. Goren, T. Ozturk, G. Topcu, 'Determination of volatile organic compounds in fourty five Salvia species by thermal desorption-GC-MS technique " Rec. Nat. Prod. 2016; 10:659-700.
Güzel S, Özay Y, Kumaş M, et al. Wound healing properties, antimicrobial and antioxidant activities of Salvia kronenburgii Rech. f. and Salvia euphratica Montbret, Aucher & Rech. f. var. euphratica on excision and incision wound models in diabetic rats. Biomed Pharmacother. 2019; 111:1260-1276. https://doi.org/10.1016/j.biopha.2019.01.038
Ozay Y, Guzel S, Gokalp Ozkorkmaz E, et al. Biochemical, Histopathologic, and Genotoxic Effects of Ethanol Extract of Salvia hypargeia (Fisch. & Mey.) on Incisional and Excisional Wounded Diabetic Rats. J Invest Surg. 2021; 34(1):7-19. https://doi.org/10.1080/08941939.2019.1590483
Martínez-Cruz O, Paredes-López O. Phytochemical profile and nutraceutical potential of chia seeds (Salvia hispanica L.) by ultra high performance liquid chromatography. J Chromatogr A. 2014; 1346:43-48. https://doi.org/10.1016/j.chroma.2014.04.007
Chen L, Kang YH. Antioxidant and enzyme inhibitory activities of Plebeian herba (Salvia plebeia R. Br.) under different cultivation conditions. J Agric Food Chem. 2014; 62(10):2190-2197. https://doi.org/10.1021/jf404570s
Perry NS, Bollen C, Perry EK, Ballard C. Salvia for dementia therapy: review of pharmacological activity and pilot tolerability clinical trial. Pharmacol Biochem Behav. 2003; 75(3):651-659. https://doi.org/10.1016/S0091-3057(03)00108-4
Tildesley NTJ, Kennedy DO, Perry EK, Ballard CG, Savelev S, Wesnesa KA, Scholey AB. Salvia lavandulaefolia(Spanish Sage) enhances memory in healthy young volunteers. Pharmacology, Biochemistry and Behavior 2003; 75:669-674. https://doi.org/10.1016/S0091-3057(03)00122-9
Ghorbani A, Esmaeilizadeh M. Pharmacological properties of Salvia officinalis and its components. J Tradit Complement Med. 2017
(4):433-440. Published 2017 Jan 13. https://doi.org/10.1016/j.jtcme.2016.12.014
Krajcovicova Z, Meluš, V (2013). Bioactivity and potential health benefits of Rosmarinic acid. Minireview. University Review, 2013; 7(2):8-14.
Ngo SN, Williams DB, Head RJ. Rosemary and cancer prevention: preclinical perspectives. Crit Rev Food Sci Nutr. 2011; 51(10):946-954. https://doi.org/10.1080/10408398.2010.490883
Petersen M, Abdullah Y, Benner J, et al. Evolution of rosmarinic acid biosynthesis. Phytochemistry. 2009; 70(15-16):1663-1679. https://doi.org/10.1016/j.phytochem.2009.05.010
Durling NE, Catchpole OJ, Grey JB, et al. Extraction of phenolics and essential oil from dried sage (Salvia officinalis) using ethanol-water mixture. Food Chemistry, 2007; 101(4):1417-1424. https://doi.org/10.1016/j.foodchem.2006.03.050
More SV, Kumar H, Cho DY, Yun YS, Choi DK. Toxin-Induced Experimental Models of Learning and Memory Impairment. Int J Mol Sci. 2016; 17(9):1447. https://doi.org/10.3390/ijms17091447
Lopresti AL. Salvia (Sage): A Review of its Potential Cognitive-Enhancing and Protective Effects. Drugs R D. 2017; 17(1):53-64. https://doi.org/10.1007/s40268-016-0157-5
Perry EK, Pickering AT, Wang WW, Houghton PJ, Perry NS. Medicinal plants and Alzheimer's disease: from ethnobotany to phytotherapy. J Pharm Pharmacol. 1999; 51(5):527-534. https://doi.org/10.1211/0022357991772808
Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. J Clin Pharm Ther. 2003; 28(1):53-59. https://doi.org/10.1046/j.1365-2710.2003.00463.x
Miroddi M, Navarra M, Quattropani MC, Calapai F, Gangemi S, Calapai G. Systematic review of clinical trials assessing pharmacological properties of Salvia species on memory, cognitive impairment and Alzheimer's disease. CNS Neurosci Ther. 2014; 20(6):485-495. https://doi.org/10.1111/cns.12270
Published
Abstract Display: 875 
PDF Downloads: 673 PDF Downloads: 39 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.